Transcatheter vs. Surgical Aortic Valve Replacement: 7-Year Outcomes in Low-Risk Patients
Ozempic and Cardiovascular Risk: new Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer Look at the SELECT Trial
A major clinical trial,the SELECT trial,has revealed a potential increased risk of serious cardiovascular events – including heart attack,stroke,and cardiovascular death - in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The study, involving over 17,600 participants, initially aimed to determine if semaglutide could reduce the risk of these events, but the results showed the opposite effect in a specific subset of patients.
Specifically, the trial observed a 24% increased risk of cardiovascular events in the semaglutide group. While the primary outcome didn’t reach statistical meaning across the entire study population, a closer examination revealed a statistically significant increase in risk among patients with a prior heart attack.
Who is Affected and Why This Matters
this finding is especially significant for the estimated 16.7 million Americans with heart disease and obesity. Ozempic and similar drugs (like Wegovy, which contains the same active ingredient, semaglutide, but at a higher dose) have become incredibly popular for weight loss, and are frequently enough prescribed *off-label* for this purpose. The SELECT trial focused on patients *with established cardiovascular disease*, a population not necessarily representative of all those using these medications.
However, the results raise concerns about potential risks even in individuals without a prior cardiovascular event, especially given the widespread use of semaglutide. The increased risk observed warrants a careful re-evaluation of the benefit-risk profile for these drugs, particularly in vulnerable populations.
Understanding the SELECT Trial Methodology
the SELECT trial was a randomized, double-blind, placebo-controlled trial conducted across 30 countries. Participants had a body mass index (BMI) of 27 or higher, established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease), and were not diagnosed with diabetes. They received either 2.4 mg of semaglutide or a placebo, in addition to standard of care, for an average of 3.4 years.
The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction (heart attack), nonfatal stroke, or unstable angina requiring hospitalization. Researchers meticulously tracked these events, leading to the observed difference between the two groups.
Key data Points: A Summary Table
| Outcome | Semaglutide Group (n=8,831) | Placebo Group (n=8,802) | Hazard Ratio (HR) | P-value |
|---|---|---|---|---|
| Cardiovascular Death | 3.7% | 3.9% | 0.95 | 0.66 |
| Nonfatal Myocardial Infarction | 2.6% | 2.2% | 1.18 | 0.37 |
| Nonfatal Stroke | 1.7% | 1.3% | 1.31 | 0.24 |
| Unstable Angina | 1.2% | 0.9% | 1.33 | 0.18 |
| Composite Cardiovascular Event | 6.6% | 5.3% | 1.24 | 0.08 |
What Does This Mean for Patients Currently Taking Ozempic?
If you are taking semaglutide and have a history of cardiovascular disease, it is crucial to discuss these findings with your